Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Search
European Election: Europe needs our vote
This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Dortmund
The Boehringer Ingelheim microParts GmbH in Dortmund manufactures and advances the technology of the RESPIMAT®.
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Registration Microbial Expert Workshop
Connect with our microbial specialists in Boston
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Welcome to Innovation at Boehringer Ingelheim
Watch our video and find out more about innovation at Boehringer Ingelheim.
Accessibility Statement
Accessability Statement
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Retinal Diseases
Retinal Diseases
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
More Cherished Moments
Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.
Yanina Donatini
Yanina Donatini, Head of ITM&S Content Production, jumped at the chance to fulfill her dreams within the Information Technology division at Boehringer Ingelheim.
Spain
Our facility in Spain is home to Regulatory Affairs Services and two technology hubs. Explore career opportunities in Spain or our 170 global locations.
The Research Process
The Research Process
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Microbial Manufacturing Platform for Non-Platform Proteins
Microbial Manufacturing Platform for Non-Platform Proteins